Journal of Clinical Oncology, Vol 12, 1458-1467, Copyright © 1994 by American Society of Clinical Oncology

ARTICLES

Phase I study of docetaxel administered as a 1-hour intravenous infusion on a weekly basis

E Tomiak, MJ Piccart, J Kerger, S Lips, A Awada, D de Valeriola, C Ravoet, D Lossignol, JP Sculier and V Auzannet
Service de Medecine et Laboratoire d'Investigation, Clinique H.J. Tagnon, Institut Jules Bordet, Centre des Tumeurs de l'Universite Libre de Bruxelles, Brussels, Belgium.

PURPOSE: This phase I study of Taxotere (RP 56976, NSC 628503; docetaxel, Rhone-Poulenc Rorer, Antony, France) was undertaken to determine the maximum-tolerated dose (MTD), toxic effects, and basic pharmacokinetics of a day-1 and -8 schedule of this novel semisynthetic product related to Taxol (paclitaxel; Bristol-Myers Squibb, Wallingford, CT). PATIENTS AND METHODS: Thirty-two eligible patients with refractory solid malignancies have been treated with a 1-hour infusion of Taxotere on a day-1 and -8 schedule every 3 weeks as long as patients maintained a polymorphonucleotide count > or = 1,500/microL and a platelet count > or = 100,000/microL. Dose levels tested have ranged between 20 and 110 mg/m2 per course. RESULTS: Considering 128 assessable courses, the main toxicities have been neutropenia (which was dose-limiting), asthenia, alopecia, hypersensitivity reactions, skin toxicity, and edema. No significant cardiac or platelet toxicity has been observed. Seven patients have had aggravation of preexisting paresthesias or new onset of sensory symptoms during Taxotere treatment. The MTD at this schedule appears to be 110 mg/m2 per course, with six of 10 patients at this level experiencing severe toxicity. Five partial remissions have been observed in four heavily pretreated patients with breast cancer and in one patient with adenocarcinoma of unknown origin. Two patients with ovarian cancer have had meaningful decreases in CA125 levels. CONCLUSION: Like Taxol, this novel chemotherapeutic agent appears to possess promising activity in patients with refractory breast and ovarian neoplasms, with tolerable toxicities. Using this schedule, 100 mg/m2 per course is the recommended dose for future phase II trials.
CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				A. C. Mita, L. A. Hammond, P. L. Bonate, G. Weiss, H. McCreery, S. Syed, M. Garrison, Q. S.C. Chu, J. S. DeBono, C. B. Jones, et al. Phase I and Pharmacokinetic Study of Tasidotin Hydrochloride (ILX651), a Third-Generation Dolastatin-15 Analogue, Administered Weekly for 3 Weeks Every 28 Days in Patients with Advanced Solid Tumors Clin. Cancer Res., September 1, 2006; 12(17): 5207 - 5215. [Abstract] [Full Text] [PDF]

				A. Eniu, F. M. Palmieri, and E. A. Perez Weekly Administration of Docetaxel and Paclitaxel in Metastatic or Advanced Breast Cancer Oncologist, October 1, 2005; 10(9): 665 - 685. [Abstract] [Full Text] [PDF]

				J. D. Hainsworth Practical Aspects of Weekly Docetaxel Administration Schedules Oncologist, September 1, 2004; 9(5): 538 - 545. [Abstract] [Full Text] [PDF]

				P. A. Vasey Role of Docetaxel in the Treatment of Newly Diagnosed Advanced Ovarian Cancer J. Clin. Oncol., May 15, 2003; 21(90100): 136s - 144. [Abstract] [Full Text] [PDF]

				A. Goncalves, F. Viret, J. Ciccolini, D. Genre, G. Gravis, M. Giovanini, J. Camerlo, J. Catalin, D. Maraninchi, and P. Viens Phase I and Pharmacokinetic Study of Escalating Dose of Docetaxel Administered with Granulocyte Colony-stimulating Factor Support in Adult Advanced Solid Tumors Clin. Cancer Res., January 1, 2003; 9(1): 102 - 108. [Abstract] [Full Text] [PDF]

				H. J. Stemmler, S. Kenngott, H. Diepolder, and V. Heinemann Gastrointestinal toxicity associated with weekly docetaxel treatment Ann. Onc., June 1, 2002; 13(6): 978 - 981. [Abstract] [Full Text] [PDF]

				B. S. Glisson, B. A. Murphy, G. Frenette, F. R. Khuri, and A. A. Forastiere Phase II Trial of Docetaxel and Cisplatin Combination Chemotherapy in Patients With Squamous Cell Carcinoma of the Head and Neck J. Clin. Oncol., March 15, 2002; 20(6): 1593 - 1599. [Abstract] [Full Text] [PDF]

				B. Esmaeli, G. Hortobagyi, F. Esteva, V. Valero, M. A. Ahmadi, D. Booser, N. Ibrahim, E. Delpassand, and R. Arbuckle Canalicular stenosis secondary to weekly docetaxel: a potentially preventable side effect Ann. Onc., February 20, 2002; 13(2): 218 - 221. [Abstract] [Full Text] [PDF]

				W. C. Zamboni, M. J. Egorin, D. A. Van Echo, R. S. Day, B. R. Meisenberg, S. E. Brooks, L. A. Doyle, N. N. Nemieboka, J. M. Dobson, N. S. Tait, et al. Pharmacokinetic and Pharmacodynamic Study of the Combination of Docetaxel and Topotecan in Patients With Solid Tumors J. Clin. Oncol., September 18, 2000; 18(18): 3288 - 3294. [Abstract] [Full Text] [PDF]

				T. Kurata, Y. Shimada, T. Tamura, N. Yamamoto, I. Hyodo, T. Saeki, S. Takashima, K. Fujiwara, H. Wakasugi, and M. Kashimura Phase I and Pharmacokinetic Study of a New Taxoid, RPR 109881A, Given as a 1-Hour Intravenous Infusion in Patients With Advanced Solid Tumors J. Clin. Oncol., September 17, 2000; 18(17): 3164 - 3171. [Abstract] [Full Text] [PDF]

				N. Yamamoto, T. Tamura, Y. Kamiya, I. Sekine, H. Kunitoh, and N. Saijo Correlation Between Docetaxel Clearance and Estimated Cytochrome P450 Activity by Urinary Metabolite of Exogenous Cortisol J. Clin. Oncol., June 11, 2000; 18(11): 2301 - 2308. [Abstract] [Full Text] [PDF]

				H. J. Burstein, J. Manola, J. Younger, L. M. Parker, C. A. Bunnell, R. Scheib, U. A. Matulonis, J. E. Garber, K. D. Clarke, L. N. Shulman, et al. Docetaxel Administered on a Weekly Basis for Metastatic Breast Cancer J. Clin. Oncol., March 13, 2000; 18(6): 1212 - 1219. [Abstract] [Full Text] [PDF]

				T. G Davidson Anemia and fatigue in cancer patients Journal of Oncology Pharmacy Practice, December 1, 1998; 4(4_suppl): S5 - S11. [Abstract] [PDF]

				Y. F. Lam, C. J. Chan, and J. G Kuhn Review : Pharmacokinetics and pharmacodynamics of the taxanes Journal of Oncology Pharmacy Practice, June 1, 1997; 3(2): 76 - 93. [Abstract] [PDF]